Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ADC Therapeutics SAADCT · Entity 6502 | Chief Accounting Officer | February 13, 2026 | February 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ADC Therapeutics SA
Report date February 13, 2026 · Filed February 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 128,224 |
Ending reported balance
After 2026-02-13 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-02-13 · Grant · Acquired 62,900 · Balance 133,657 F1: Represents Common Shares to be delivered in settlement of a restricted share unit award which vests one-third on the first anniversary of the grant date, which grant date is February 13, 2026, and then one-third on each anniversary date thereafter, upon continued service through the designated vesting event. Row 2 · 2026-02-13 · Tax withholding · Disposed 5,433 · Balance 128,224 F2: Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents Common Shares to be delivered in settlement of a restricted share unit award which vests one-third on the first anniversary of the grant date, which grant date is February 13, 2026, and then one-third on each anniversary date thereafter, upon continued service through the designated vesting event.
F2: Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 13, 2026 Filed Feb 18, 2026 17:44 UTC | ADC Therapeutics SA ADCT · Entity 6502 | Tax withholdingCommon Shares | 5,433 | $3.99 | $21,677.67 |
DisclosureSEC source: 0001628280-26-009283 · wk-form4_1771454641.xml · nonDerivative · entry 2 Kallebo Lisa Michelle · CIK 0002000724 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 128,224 F2 · shares: Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted. Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 17:44 UTC | ADC Therapeutics SA ADCT · Entity 6502 | GrantCommon Shares | 62,900 | $3.99 | $250,971.00 |
DisclosureSEC source: 0001628280-26-009283 · wk-form4_1771454641.xml · nonDerivative · entry 1 Kallebo Lisa Michelle · CIK 0002000724 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 133,657 F1 · shares: Represents Common Shares to be delivered in settlement of a restricted share unit award which vests one-third on the first anniversary of the grant date, which grant date is February 13, 2026, and then one-third on each anniversary date thereafter, upon continued service through the designated vesting event. Read SEC document |
| December 06, 2025 Filed Dec 9, 2025 17:09 UTC | ADC Therapeutics SA ADCT · Entity 6502 | Tax withholdingCommon Shares | 7,140 | $3.29 | $23,490.60 |
DisclosureSEC source: 0001628280-25-056170 · wk-form4_1765318181.xml · nonDerivative · entry 1 Kallebo Lisa Michelle · CIK 0002000724 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,757 F1 · kind: Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted. F1 · acquired: Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted. Read SEC document |
| February 13, 2025 Filed Feb 14, 2025 18:22 UTC | ADC Therapeutics SA ADCT · Entity 6502 | GrantCommon Shares | 41,900 | $1.61 | $67,459.00 |
DisclosureSEC source: 0001628280-25-005861 · wk-form4_1739575330.xml · nonDerivative · entry 1 Kallebo Lisa Michelle · CIK 0002000724 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,897 F1 · shares: Represents Common Shares to be delivered in settlement of a restricted share unit award which vests one-third on the first anniversary of the grant date, which grant date is February 13, 2025, and then one-third on each anniversary date thereafter, upon continued service through the designated vesting event. Read SEC document |
| December 06, 2024 Filed Dec 9, 2024 20:39 UTC | ADC Therapeutics SA ADCT · Entity 6502 | Tax withholdingCommon Shares | 6,503 | $3.13 | $20,354.39 |
DisclosureSEC source: 0001628280-24-050542 · wk-form4_1733794766.xml · nonDerivative · entry 1 Kallebo Lisa Michelle · CIK 0002000724 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,997 F1 · kind: Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted. F1 · acquired: Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.